A Phase 1b/2 Randomized Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectab

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Colorectal Cancer
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    To participate in the study the following conditions must be met:
    1. 1) Has a type of cancer called colorectal adenocarcinoma that has spread to other parts of the body or is in a spot where surgery is not an option
    2. 2) Availability of tumor

You may not be eligible for this study if the following are true:

  • You will not be able to participate in the study if you have had:
    1. 1) Confirmed if the tumor has MSI-H (high microsatellite instability) by using a method called immunohistochemistry (IHC) either at a local lab or a central lab or by using a met

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.